AEMD logo

AETHLON MEDICAL INC

AEMDNASDAQ
πŸ† #4017 by market capEarnings Aug 13US Equity
$3.18β–² $0.12 (+3.75%)
πŸŒ™ After hours$3.06β–Ό 3.67%Regular close Β· extended-hours price shown
1hβ€”
24hβ–² 3.8%
7dβ–Ό 1.5%
14dβ–² 12.6%
30dβ–Ό 7.2%
1yβ–Ό 99.5%
🏦Market Cap
$8M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+96.5%
High Growth
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
3.5x
Fair
Otter Score
47
Weak

Trading Snapshot

Day Range
$3.15 – $3.22
52-Week Range
$2.62 – $137.00
Volume
$2.98B
Avg Volume
$2.86B
Shares Outstanding
2.6M
Next Earnings
Sep 22, 2026

Fundamentals Snapshot

Annual Revenue
$570,003
Last Q Revenue
$136,184
P/E Ratio
β€”
P/S Ratio
3.5x
EPS (TTM)
$-46.92
Dividend Yield
β€”

Why Investors Own AEMD

  • βœ“High-growth profile β€” revenue up -4.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 79% gross margin and 21% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$570,003β–Ό βˆ’3.7% YoY
Gross Margin (TTM)
79.4%β–² +3.8% YoY
Operating Income (TTM)
$135,661β–Ό βˆ’3.7% YoY
Free Cash Flow (TTM)
$119,701β–Ό βˆ’3.7% YoY

About AETHLON MEDICAL INC

Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
47/100

Analyst Price Target

β“˜
Average Target
$3.06
β–Ό βˆ’3.8% Downside
High Target$3.76
Low Target$2.73
Based on 19 analysts

Latest News & Updates